Market Place
Sourcing Support
Roche blasts `act of counterfeiting` for cancer drug in Pakistan
26 Sep 2023 //
FIERCE PHARMA
Patient deaths taint Roche`s landmark adjuvant liver cancer data
16 Apr 2023 //
FIERCE PHARMA
Roche`s Tecentriq, Avastin combo cuts risk of liver cancer returning
20 Jan 2023 //
BIOPHARMADIVE
Another Avastin biosimilar joins the party as Roche`s grip on the market loosens
28 Sep 2022 //
ENDPTS
Genentech`s Biologic AVASTIN(Bevacizumab) Receives Approval in the U.S.
18 Sep 2022 //
FDA
Celltrion’s Vegzelma receives EC approval for cancer treatments
19 Aug 2022 //
PHARMACEUTICAL TECHNOLOGY
Microcap`s effort to take on Eylea with Avastin biosimilar faces FDA roadblock
01 Jun 2022 //
ENDPTS
Celltrion finishes global patent agreement for Avastin biosimilar CT-P16
20 May 2022 //
KOREABIOMED
Fresenius agrees two acquisitions to bolster Kabi drugs unit
01 Apr 2022 //
REUTERS
Orphan drug tax credit on the chopping block again under Dem spending bill
29 Oct 2021 //
ENDPTS
Novartis launches review of Sandoz
27 Oct 2021 //
FIERCEPHARMA
Celltrion applies for product approval for Avastin biosimilar in EU
12 Oct 2021 //
KOREABIOMED
FDA ends summer with fresh batch of breakthrough device designations
10 Sep 2021 //
MEDTECHDIVE
Therapeutic Solutions Files New Drug Application with FDA for Cancer
30 Aug 2021 //
PRNEWSWIRE
UHC Changes Its Bevacizumab Policy Following AAO Complaint
19 Aug 2021 //
CENTERFORBIOSIMILARS
J&J, Amgen and Roche face growing biosimilar competition
12 Aug 2021 //
FIERCEPHARMA
Revision of Package Insert of Opdivo with Bevacizumab
21 Jun 2021 //
PRESS RELEASE
AZ takes PARP battle against GSK to court
08 Jun 2021 //
FIERCEPHARMA
AZ takes PARP battle against GSK to court
07 Jun 2021 //
FIERCEPHARMA
Biocon tanks 4% as USFDA defers decision on Avastin biosimilar application
28 Dec 2020 //
INDIATIMES
Biocon tanks 4% as USFDA defers decision on Avastin biosimilar application
28 Dec 2020 //
INDIATIMES
USFDA informs Biocon Biologics, Mylan of deferred action Avastin license
25 Dec 2020 //
INDIATIMES
Bio-Thera Solutions Submits Marketing Authorization Application MAA for BAT1706
25 Nov 2020 //
BUSINESSWIRE
European Commission approves Roche’s Tecentriq in combination with Avastin
02 Nov 2020 //
PRESS RELEASE
Genentech, Amgen Settle Herceptin, Avastin Biosimilar Disputes
09 Jul 2020 //
BIGMOLECULEWATCH
New BPCIA Complaint: Genentech Seeks to Block Samsung Bioepis’s Proposed AVASTIN
30 Jun 2020 //
BIGMOLECULEWATCH
How Orphan Drug Policy Could Impede Access To COVID-19 Treatments
25 Jun 2020 //
RAPS
NMPA Accepts Bio-Thera Solutions’ Biologics License Application for BAT1706
22 Jun 2020 //
BUSINESSWIRE
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People
29 May 2020 //
BUSINESSWIRE
Merck`s Keytruda doubles time to colorectal cancer progression
28 May 2020 //
FIERCE PHARMA
Lynparza gets broader US ovarian cancer approval
12 May 2020 //
CISION
AZ, Merck`s Lynparza will face GSK in wider ovarian cancer pool
08 May 2020 //
FIERCE PHARMA
Pfizer hits its biosimilar stride
28 Jan 2020 //
BIOPHARMADIVE
Pfizer Rolls Out Japan’s Second Rituxan Biosimilar
20 Jan 2020 //
PHARMA JAPAN
Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States
13 Jan 2020 //
GLOBENEWSWIRE
ImmunoGen maps new path to accelerated approval
17 Dec 2019 //
ENDPT NEWS
Roche takes aim at Bayer`s liver cancer share with big Tecentriq-Avastin win
28 Nov 2019 //
FIERCE PHARMA
FDA Accepts Samsung Bioepis’ BLA for SB8 Bevacizumab Biosimilar Candidate
20 Nov 2019 //
BIO SPACE
5 updates from Teva`s busy quarter:A new CFO, a biosimilar launch &migraine miss
09 Nov 2019 //
BIOPHARMA DIVE
Pfizer unveils biosimilar launch plans and shares view on US market
08 Nov 2019 //
BIOPROCESS INTERNATIONAL
Teva set to launch U.S. biosim of Roche`s blockbuster Rituxan
08 Nov 2019 //
FIERCE PHARMA
Chugai Pharma announces +ve results from phase III IMbrave150
22 Oct 2019 //
PHARMABIZ
As Biosimilars Emerge in Oncology and Rare Disease
17 Oct 2019 //
CENTERFORBIOSIMILARS
Roche limits biosim damage to cancer blockbusters, but it`s still early
17 Oct 2019 //
FIERCE PHARMA
FDA requests additional time for Flexion`s NDA
15 Oct 2019 //
ENDPTS
AbbVie`s Humira, Roche`s Rituxan top ICER`s list of worst price-hike offenders
09 Oct 2019 //
FIERCE PHARMA
AstraZeneca, Merck strengthen lead in PARP drug class
30 Sep 2019 //
BIOPHARMADIVE
FDA OKs Roche`s Rituxan for rare blood vessel inflammation diseases
27 Sep 2019 //
SEEKINGALPHA
Biosimilars will leave a $10B gap in Roche`s sales: exec
19 Sep 2019 //
FIERCE PHARMA
Biosimilars will leave a $10B gap in Roche`s sales: exec
18 Sep 2019 //
FIERCE PHARMA
Early snapshot of Adverum`s eye gene therapy sparks concern about vision loss
13 Sep 2019 //
ENDPTS
Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bid
13 Sep 2019 //
PHARMAPHORUM
Roche`s Tecentriq excels in another lung cancer study
13 Sep 2019 //
ENDPOINTSNEWS
Look out Alexion, Roche breaks out the details on its rival rare CNS drug
13 Sep 2019 //
ENDPOINTSNEWS
Roche`s Tecentriq comes up short in squamous lung cancer
10 Sep 2019 //
FIERCE PHARMA
Bristol-Myers Squibb`s Opdivo fails 3rd test in tough-to-treat brain cancer
07 Sep 2019 //
FIERCEPHARMA
Roche`s Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals
07 Sep 2019 //
FIERCEPHARMA
Genentech settles fight over cancer drug trade secrets with Taiwan`s JHL
06 Sep 2019 //
FIERCEPHARMA
Amgen, Allergan biosimilar Roche`s blockbuster Rituxan clears another US Study
23 Aug 2019 //
ENDPTS
Dr Reddy`s launches Roche`s Avastin biosimilar in India
19 Aug 2019 //
ECONOMICTIMES
